VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Authors: Dongsheng Yue, Wenxiang Wang, Haibo Liu, Qian Chen, C. Chen, Lei Liu, P. Zhang, Genming Zhao, Fan Yang, Guang Han, Ying Cheng, Baofa Yu, Yue Yang, Hui Chen, Jie Jiang, Bo Yao, Sheng Wang, Ruikang K. Wang, Wei Zheng, C. Wang - Annals of Oncology 2024 cited by 37